05/15/2025
3:06 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2025
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form DEFA14A | |
05/07/2025
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/28/2025
3:10 PM | EyePoint Pharmaceuticals (Filer)
| Form DEFA14A | |
03/20/2025
3:06 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2025
3:05 PM | EyePoint Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/05/2025
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2025
8:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2025
5:37 PM | EyePoint Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
02/12/2025
8:33 AM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SCHEDULE 13G/A | |
02/11/2025
5:19 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for EYPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
02/11/2025
5:19 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/11/2025
5:19 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2025
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/27/2025
11:58 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/08/2025
3:11 PM | EyePoint Pharmaceuticals (Issuer)
Sanders Reginald J. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/08/2025
3:14 PM | EyePoint Pharmaceuticals (Issuer)
Sanders Reginald J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/08/2025
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/07/2025
3:03 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | EyePoint Pharmaceuticals (Issuer)
Landis John B. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:04 PM | ANDO GORAN (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:05 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:05 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/04/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
2:10 PM | Cormorant Asset Management, LP (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/12/2024
1:31 PM | EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/12/2024
8:33 AM | Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2024
7:54 AM | EyePoint Pharmaceuticals (Subject)
FEDERATED HERMES, INC. (Filed by)
FEDERATED HERMES, INC. (Filed by)
| Form SC 13G | |
11/04/2024
10:57 AM | EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
10/31/2024
3:16 PM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
11:51 AM | EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
| Form SCHEDULE 13G/A | |
10/30/2024
3:20 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
4:17 PM | EyePoint Pharmaceuticals (Filer)
| Form 424B5 | |
10/28/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
A new financial chapter (Ad) Porter Stansberry says what happened last week could become the defining legacy of his financial publishing career.
In a special event watched by thousands, he unveiled what he calls “the boldest undertaking” he’s ever attempted — a real-money initiative that will document every trade, decision, win, and loss in pursuit of a million-dollar mission. And the results are already surprising. One early beta tester tripled her investment income in just three trades. If you missed the event, he’s republishing the message he sent to attendees right after it ended. |
10/24/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/23/2024
3:34 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
2:24 PM | BlackRock, Inc. (Filed by)
EyePoint Pharmaceuticals (Subject)
| Form SC 13G | |
10/15/2024
10:58 AM | EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:02 PM | EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/04/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/21/2024
3:32 PM | DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/18/2024
11:15 PM | EyePoint Pharmaceuticals (Filer)
| Form EFFECT | |
08/08/2024
3:42 PM | EyePoint Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
08/08/2024
3:46 PM | EyePoint Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/07/2024
6:00 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/26/2024
3:47 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
3:24 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:00 PM | EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:03 PM | EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:04 PM | Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/26/2024
8:25 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2024
3:16 PM | ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/04/2024
3:28 PM | EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
3:22 PM | Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/28/2024
6:05 AM | EyePoint Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Buy EYPT Stock Free EYPT Stock Alerts